SecBot SecBot
6-K ·Filed Nov 13, 2026

VALN

Valneva SE
NEUTRAL
Impact 4/10
Horizonmonths Processed3d 13h ago SEC0001628280-26-073616
Notable filing: 6-K
Actionable Insight • Neutral

Monitor for next-step clinical development plans for S4V2 and for IXCHIQ real-world effectiveness data from the Brazilian campaign. No revenue or earnings guidance was provided.

DirectionNeutral
Confidencemedium
Horizonmonths

Drugs in focus

VALN drug pipeline →

IXCHIQ

▼ Bearish Named in this 6-K
Impact
Phase
Approved
Time to market
Already approved and marketed in the EU, Canada, Brazil and select other markets (approved November 2023 in the US, but US and UK authorizations have been withdrawn).
Next catalyst
None dated

What to watchIXCHIQ's commercial future hinges on whether Valneva can rebuild regulatory trust after the US and UK withdrawals. The positive five-year durability data (94% seroresponse) supports the vaccine's efficacy case, but safety concerns remain the dominant overhang. Valneva reports nine-month 2026 results on November 24, which will provide the clearest read on IXCHIQ's ongoing revenue contribution from EU, Canada and Brazil markets.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$5.66
T+0 close · Nov 13, 2026 · via day close
Latest settled
−0.18%
T+1 · $5.65
Vs SPY
+1.73%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $5.66entry
  2. T+1 · 16h ago −0.18%α +1.73% · $5.65
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Valneva reported positive five-year antibody persistence data for its chikungunya vaccine IXCHIQ, showing 94% seroresponse in 221 evaluable participants, and positive Phase 2 results for its Shigella vaccine candidate S4V2, which met its primary endpoint in a CHIM trial. These are clinical development updates, not financial results; no revenue or EPS figures were reported.

Key Facts

  • 94% of 221 evaluable participants maintained seroresponse five years after a single dose of IXCHIQ
  • Antibody persistence in adults 65+ was comparable to adults 18-64
  • Phase 2 infant trial for S4V2 showed statistically significant immune responses for all four Shigella serotypes
  • Phase 2 CHIM trial for S4V2 met its primary endpoint with statistically significant reduction in shigellosis incidence
  • FDA granted Fast Track designation to S4V2 in 2024
  • Brazilian Pilot Vaccination Strategy vaccinated nearly 80,000 adults with IXCHIQ between Feb-Oct 2026

Financial Impact

No financial figures reported; clinical data updates only

Risk Factors

  • Clinical trial results may not predict regulatory approval or commercial success
  • S4V2 requires further dose optimization and clinical evaluation before pivotal trials
  • IXCHIQ commercial adoption depends on outbreak demand and public health campaigns

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001628280-26-073616
Document: a2026_11x09xs4v2xinfant-ch.htm0001628280-26-073616
Document: a6-kcoverpagetemplate.htm0001628280-26-073616
Document: 0001628280-26-073616-index-headers.html0001628280-26-073616
Document: 0001628280-26-073616-index.html0001628280-26-073616
Document: 0001628280-26-073616.txt0001628280-26-073616
Earnings Context (Synthetic; results releases only)0001628280-26-073616

US Market Status

Market Closed · Opens Wed (10h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026